Effects of lusutrombopag: A Synthesis of Findings from 20 Studies

  1. Home
  2. Effects of lusutrombopag
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of lusutrombopag: A Synthesis of Findings from 20 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of lusutrombopag: A Synthesis of Findings from 20 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Lusutrombopag is an oral thrombopoietin receptor agonist that has been shown to be effective in treating thrombocytopenia in patients with chronic liver disease (CLD). 10 , 20 , 7 , Lusutrombopag can increase platelet counts in CLD patients before they undergo invasive procedures, which can reduce the risk of bleeding. 10 , 15 , 13 Some studies have shown that lusutrombopag is more effective than platelet transfusions. 4 Lusutrombopag may have slightly weaker effects on patients with severe thrombocytopenia compared to those with mild thrombocytopenia and its efficacy may be decreased in patients with diabetes mellitus. 2 , 10 Lusutrombopag has also been used as a pretreatment for liver biopsy following liver transplantation. Lusutrombopag has shown efficacy and safety in repeated administrations. 10 , 14

Benefits and risks

Benefit summary

Lusutrombopag can help reduce the risk of bleeding in CLD patients by increasing platelet counts before invasive procedures. 15 , 10 It may also be a more effective and safer alternative to platelet transfusions. 4 Lusutrombopag has also shown efficacy in repeated administrations. 10 , 14

Risk summary

The main side effects of lusutrombopag include headache, nausea, fatigue, and rash. 18 Lusutrombopag may have weaker effects on patients with severe thrombocytopenia compared to those with mild thrombocytopenia and its efficacy may be decreased in patients with diabetes mellitus. 2 , 10

Comparison across studies

Commonalities across studies

Most studies have found that lusutrombopag increases platelet counts in CLD patients. 15 , 10 , 20 , Lusutrombopag has also been suggested to be a more effective and safer alternative to platelet transfusions. 4

Differences across studies

There are differences in the strength of lusutrombopag’s effects and the occurrence of side effects in some studies. 2 , 10 Lusutrombopag may also have weaker effects on patients with severe thrombocytopenia compared to those with mild thrombocytopenia and its efficacy may be decreased in patients with diabetes mellitus. 2 , 10

Consistency and contradictions in results

Several studies have shown that lusutrombopag increases platelet counts in CLD patients. However, there are differences in the strength of its effects and the occurrence of side effects, suggesting that the effects of lusutrombopag may vary among individuals. 2 , 10 The possibility of decreased efficacy in diabetic patients needs to be further investigated. 10

Considerations for real-world application

Lusutrombopag can help reduce the risk of bleeding in CLD patients before invasive procedures. 15 , 10 However, the strength of its effects and the occurrence of side effects may vary among individuals. It’s important to discuss with your doctor about the right treatment option for you. 2 , 10

Limitations of current research

More research is needed on lusutrombopag. It is particularly important to conduct large-scale clinical trials with a larger number of patients to investigate the effects and safety of lusutrombopag in specific patient groups like diabetic patients, as well as long-term effects and combined effects of lusutrombopag with other treatments. 10 , 2

Future research directions

Future research on lusutrombopag should include large-scale clinical trials involving a greater number of patients. These trials should investigate the effects and safety of lusutrombopag in specific patient groups like diabetic patients, as well as long-term effects and combined effects of lusutrombopag with other treatments. 10 , 2

Conclusion

Lusutrombopag has been shown to increase platelet counts in CLD patients. 15 , 10 , 20 , However, the strength of its effects and the occurrence of side effects may vary among individuals. 2 , 10 It may be a more effective and safer alternative to platelet transfusions, but discussing the right treatment option with your doctor is crucial. 4

Literature analysis of 20 papers
Positive Content
20
Neutral Content
0
Negative Content
0
Article Type
2
2
2
5
19
1.

Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist.

Author: KatsubeTakayuki, WajimaToshihiro, FukuharaTakahiro, KanoTakeshi

Safe with food

Three studies showed that lusutrombopag, a novel thrombopoietin receptor agonist, can be administered with or without food, including dairy products, mineral supplements, or antacids, without significant alterations in its pharmacokinetic parameters.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study.

Author: FuruichiYoshihiro, TakeuchiHirohito, UojimaHaruki, AtsukawaMasanori, AraiTaeang, AraseYoshitaka, KakoMakoto, HidakaHisashi, ItoiTakao

Platelet count increase

Lusutrombopag effectively increases platelet count in patients with severe thrombocytopenia. This study aimed to clarify the efficacy of Lusutrombopag on patients with mild thrombocytopenia (platelet count > 50 000/µL) by unifying background factors by propensity score matching.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

3.

Thrombocytopenia in Chronic Liver Disease: New Management Strategies.

Author: NillesKathy M, FlammSteven L

Increase platelet count

Thrombocytopenia is common in advanced liver disease, often requiring invasive procedures. Thrombopoietin receptor agonists, such as avatrombopag and lusutrombopag, have shown efficacy in increasing platelet counts in outpatient settings for patients with advanced liver disease requiring procedures.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.

Author: TateishiRyosuke, SeikeMasataka, KudoMasatoshi, TamaiHideyuki, KawazoeSeiji, KatsubeTakayuki, OchiaiToshimitsu, FukuharaTakahiro, KanoTakeshi, TanakaKatsuaki, KurokawaMineo, YamamotoKazuhide, OsakiYukio, IzumiNamiki, ImawariMichio

RFA safety
Thrombocytopenia treatment
Lusutrombopag side effects

This study evaluated the efficacy and safety of lusutrombopag for the treatment of thrombocytopenia in chronic liver disease (CLD) patients before percutaneous liver radiofrequency ablation (RFA) for primary hepatic cancer.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

8.

Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.

Author: OrmeMichelle E, BentleyRoy, MarcellaStephen, Peck-RadosavljevicMarkus, PerardRodolphe, WedemeyerHeiner, YoshijiHitoshi, AgarwalKosh, DusheikoGeoffrey

Reduced platelet transfusion

Lusutrombopag, an oral thrombopoietin receptor agonist, has been shown to reduce the need for preoperative platelet transfusions in patients with chronic liver disease and severe thrombocytopenia. This analysis assessed the efficacy and safety of lusutrombopag in these patients undergoing planned invasive procedures.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

9.

Avoidance of platelet transfusion with readministration of lusutrombopag before radiofrequency ablation in hepatocellular carcinoma:a case report.

Author: KotaniSatoshi, KohgeNaruaki, TsukanoKousuke, OgawaSayaka, YamanouchiSatoshi, KusunokiRyusaku, AimiMasahito, MiyaokaYouichi, FujishiroHirofumi

Lusutrombopag readministration
Platelet transfusion avoidance
HCC recurrence

This case study describes a patient with liver cirrhosis and hepatocellular carcinoma (HCC) who successfully avoided platelet transfusions before radiofrequency ablation (RFA) by receiving lusutrombopag. Lusutrombopag effectively increased platelet count, allowing for RFA without transfusion.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Japanese

10.

Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures.

Author: NishidaYuno, KawaokaTomokazu, ImamuraMichio, NambaMaiko, FujiiYasutoshi, UchikawaShinsuke, OhyaKazuki, DaijoKana, TeraokaYuji, MorioKei, FujinoHatsue, NakaharaTakashi, YamauchiMasami, HiramatsuAkira, TsugeMasataka, AikataHiroshi, TakahashiShoichi, HayesC Nelson, FukuharaTakayuki, TsujiKeiji, AratakiKeiko, NagaokiYuko, AisakaYasuyuki, KamadaKoji, KodamaHideaki, ChayamaKazuaki

Increased platelet count
Invasive procedure success
Reduced platelet transfusion need
Decreased efficacy in diabetes

Lusutrombopag, a thrombopoietin receptor agonist, effectively improves thrombocytopenia in patients with chronic liver disease undergoing invasive procedures. This study found that repeated lusutrombopag treatment was similarly effective and that diabetes mellitus was negatively associated with lusutrombopag response.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

12.

The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.

Author: KuterDavid J

Favorable pharmacological profile
Treatment options

Avatrombopag, a TPO-R agonist, exhibits a favorable pharmacological profile with no drug-drug interactions, food interactions, or potential for chelation, making it a promising treatment option for thrombocytopenia in various conditions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.

Author: SatoShuichi, MiyakeTatsuya, KataokaMasatoshi, IsodaKazuki, YazakiTomotaka, TobitaHiroshi, IshimuraNorihisa, KinoshitaYoshikazu

Lusutrombopag thrombocytopenia
Chronic liver disease

Lusutrombopag is a drug used to increase the number of platelets in the blood, which help stop bleeding. This study investigated the use of lusutrombopag to prevent platelet transfusions in patients with low platelet counts who are undergoing multiple surgical procedures. The study found that lusutrombopag may be helpful in preventing platelet transfusions in these patients.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease.

Author: YoshidaManami, TateishiRyosuke, HiroiShinzo, HongoYoshie, FujiwaraMasakazu, KitanishiYoshitake, IwasakiKosuke, TakeshimaTomomi, IgarashiAtaru

Bleeding risk reduction

This study aimed to compare the effects of lusutrombopag and prophylactic platelet transfusion (PT) in patients with chronic liver disease (CLD) undergoing invasive procedures. Lusutrombopag is a small-molecule thrombopoietin receptor agonist that may be an alternative to PT for preventing bleeding.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.

Author: ArmstrongNigel, BüyükkaramikliNasuh, PentonHannah, RiemsmaRob, WetzelaerPim, Huertas CarreraVanesa, SwiftStephanie, DrachenThea, RaatzHeike, RyderSteve, ShahDhwani, BuksnysTitas, WorthyGill, DuffySteven, AlMaiwenn, KleijnenJos

Thrombocytopenia treatment

This systematic review and cost-effectiveness analysis found that avatrombopag and lusutrombopag were superior to no thrombopoietin receptor agonist in avoiding both platelet transfusion and rescue therapy, but they were not cost-effective given the lack of benefit and increase in cost.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

17.

New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations.

Author: Clemons BankstonPage, Al-HoraniRami A

Thrombocytopenia treatment
Adverse effects

Three new drugs, lusutrombopag, avatrombopag, and fostamatinib, have been approved for the treatment of low platelet counts.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States.

Author: DieterichDouglas T, BernsteinDavid, FlammSteven, PockrosPaul J, ReauNancy

Thrombocytopenia treatment
Bleeding risk

This study discusses the management of thrombocytopenia, a common hematological abnormality in patients with chronic liver disease. The authors highlight the potential risks of bleeding during or after invasive procedures and the use of novel agents that target the thrombopoietin pathway as alternatives to platelet transfusion.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

19.

Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.

Author: GalloPaolo, TerraccianiFrancesca, Di PasqualeGiulia, EspositoMatteo, PicardiAntonio, Vespasiani-GentilucciUmberto

TPO agonists
Thrombocytopenia treatment
Bleeding risk
Chronic liver disease

TPO-receptor agonists, such as avatrombopag and lusutrombopag, are promising new drugs for treating thrombocytopenia in patients with chronic liver disease. They can increase platelet production, potentially reducing the need for platelet transfusions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

20.

Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.

Author: YoshidaHiroshi, YamadaHajime, NogamiWataru, DohiKeiji, Kurino-YamadaTomomi, SugiyamaKoji, TakahashiKoji, GaharaYoshinari, KitauraMotoji, HasegawaMinoru, OshimaItsuki, KuwabaraKenji

thrombocytopenia treatment

Lusutrombopag is an oral medication used to treat thrombocytopenia in patients with chronic liver disease. Preclinical studies have shown that lusutrombopag increases megakaryocyte production and platelet count by activating the thrombopoietin receptor (TPOR).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.